Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant PD-1 antibody plus docetaxel and lobaplatin for resectable non-terminal hypopharyngeal squamous cell carcinoma
ChiCTR2000033358Phase 3Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jul 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of PD-1 Monoclonal Antibody, docetaxel and lobaplatin in squamous cell carcinoma of the hypopharynx (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Disease-free survival. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
PD-1 Monoclonal Antibodydocetaxellobaplatin
03
Conditions
squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on ChiCTR2000033358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033358.